Trade Secret Royalty. The parties acknowledge that the principal value contributed by Aurora under this Agreement is the enhanced probability of identifying leads for human pharmaceutical products (or other products having commercial value) and the potential to generate multiple leads, either or both of which the parties reasonably believe will lessen the time required to bring pharmaceutical products to market and increase the efficiency of drug discovery and development processes and technologies. Additionally, the parties acknowledge that Aurora may not own or control patent applications or patents covering the manufacture, sale, use, or importation of a particular Agreement Compound or Product. Allelix acknowledges and agrees that the value it receives hereunder is in the access and use of the Screens and the Aurora Technology. Accordingly, Allelix agrees to pay those royalties and other amounts at the applicable rate specified in this Section 6.2, regardless of whether a Product is covered by a patent application or patent within the Aurora Technology.
Appears in 3 contracts
Samples: Collaboration Agreement (Aurora Biosciences Corp), Collaboration Agreement (Aurora Biosciences Corp), Collaboration Agreement (Aurora Biosciences Corp)
Trade Secret Royalty. The parties acknowledge that the principal value contributed by Aurora under this Agreement is the enhanced probability of identifying leads for human pharmaceutical products (or other products having commercial value) and the potential to generate multiple leads, either or both of which the parties reasonably believe will lessen the time required to bring pharmaceutical products to market and increase the efficiency of drug discovery and development processes and technologies. Additionally, the parties acknowledge that Aurora may not own or control patent applications or patents Patent Rights covering the manufacture, sale, use, or importation of a particular Agreement Compound or Product. Allelix Cytovia acknowledges and agrees that the value it receives hereunder is primarily in the access and use of the Screens Aurora Compounds and the Aurora Technology. Accordingly, Allelix Cytovia agrees to pay those royalties and other amounts at the applicable rate specified in this Section 6.25.2, regardless of whether a Product is covered by a patent application or patent Patent Rights within the Aurora Technology.
Appears in 1 contract